Figure 2From: Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritisProportion of patients with 20% improvement in ACR criteria (with last value carried forward [LVCF]).Back to article page